Illinois lawmakers have introduced new legislation called SB1711, the Clinical Trial Participation Act, that gives all cancer patients access to potentially life-saving breakthrough medical treatments in clinical trials.

The unanimously approved law aims to enhance patient participation and retention in cancer clinical trials, especially among underrepresented groups.

It clarifies that reimbursing patients for the out-of-pocket costs, such as expenses required to travel to a clinical study site, is not to be considered an inducement.

According to a national study, patient households making less than $50,000 per annum were almost 30% less likely to engage in clinical trials.

Lazarex Cancer Foundation said in a press statement: “Clinical trials offer advanced treatments before the general public can access them. All new treatments must complete a clinical trial before becoming FDA approved, and they must have patients enrolled to be successful.

“However, an estimated 97% of cancer patients don’t enrol because clinical trial sites are often far from home, making travel for patients both difficult and financially burdensome.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Furthermore, a similar law is currently being considered in the US states of Wisconsin, Massachusetts, Florida, and New Mexico and is already effective in California, Pennsylvania, and Texas.

In April last year, US lawmakers introduced new legislation, the Henrietta Lacks Enhancing Cancer Research Act, which would examine access to government-funded cancer clinical trials. This bill will examine how this access affects traditionally underrepresented groups.